The challenges of the current OSD outsourcing market are explained in an excellent editorial overview article in the current issue of the specialist magazine "Contract Pharma".

The article deals not only with contract manufacturing of complex new active pharmaceutical ingredients, but also with aspects of production capacity.

Aenova Chief Commercial Officer Neil Jones and Aenova Chief Scientific Officer Florent Bordet, among others, provide information on current market trends, challenges such as the bioavailability of active ingredients and explain possible solutions.

Just recently, Aenova reported on major investments for capacity expansions at the high-volume site for conventional solids at the Tittmoning site and emphasized its capabilities in the area of innovative technologies and solutions.

Read more in the current issue of "Contract Pharma" magazine.

Learn more about the capacity expansions at the high-volume site for conventional solids at the Tittmoning site and highlighted Aenova's capabilities in the area of innovative technologies and solutions.